Last $72.25 USD
Change Today +0.06 / 0.08%
Volume 1.2M
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

alkermes plc (ALKS) Snapshot

Open
$71.88
Previous Close
$72.19
Day High
$73.69
Day Low
$71.48
52 Week High
01/30/15 - $73.69
52 Week Low
10/13/14 - $38.49
Market Cap
10.6B
Average Volume 10 Days
1.2M
EPS TTM
$-0.42
Shares Outstanding
146.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALKERMES PLC (ALKS)

alkermes plc (ALKS) Related Businessweek News

View More BusinessWeek News

alkermes plc (ALKS) Details

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension and/or angina; and ZOHYDRO ER for severe pain. In addition, it is developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 33, which has completed Phase II study for modulation of brain opioid receptors; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a phase II study medicine to treat schizophrenia; ALKS 8700, a prodrug of monomethyl fumarate to treat multiple sclerosis; ALKS 7106, a small-molecule product candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary biologic cancer immunotherapy candidate. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. The company was founded in 1987 and is headquartered in Dublin, Ireland.

1,250 Employees
Last Reported Date: 02/27/14
Founded in 1987

alkermes plc (ALKS) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $810.2K
President
Total Annual Compensation: $579.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $444.1K
Chief Legal Officer, Chief Compliance Officer...
Total Annual Compensation: $435.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $435.5K
Compensation as of Fiscal Year 2013.

alkermes plc (ALKS) Key Developments

Alkermes Announces Positive Results from Phase II Schizophrenia Study

Alkermes plc has announced positive results from the 12-week, randomized, double-blind, active-controlled, dose-ranging stage of a Phase II study of ALKS 3831, an investigational, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia. ALKS 3831 is composed of samidorphan, a novel, potent mu-opioid antagonist, in combination with the established antipsychotic drug, olanzapine. Data from the 300-patient study showed that ALKS 3831 achieved the study's primary efficacy endpoint, demonstrating equivalence to olanzapine in reduction from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at Week 12.

Alkermes plc Announces Positive Results from Study of ALKS 5461 for Treatment of Depressive Disorder

Alkermes plc announced top line results from FORWARD-1, one of a series of supportive clinical studies in the comprehensive FORWARD phase 3 pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). The FORWARD-1 study was designed to evaluate the safety and tolerability of two titration schedules of ALKS 5461. In addition, the study assessed the efficacy of ALKS 5461 over an eight-week period, compared to baseline, in patients with MDD. Data from the 66-patient study showed that ALKS 5461 was generally well tolerated in both of the two titration schedules evaluated one-week and two-week dose escalation schedules. The most common adverse events in the study were nausea, constipation and dry mouth. These findings were consistent with the safety and tolerability profile seen in the 142-patient phase 2 study completed in 2013. Additionally, the exploratory efficacy analyses showed that ALKS 5461 significantly reduced depressive symptoms from baseline starting at Week One and continued to the end of the treatment period at Week Eight in patients who received either of the two titration schedules. The observed changes from baseline were clinically meaningful and statistically significant (pFORWARD-1 Study Design). The primary objective of the study was to evaluate the safety and tolerability of the two titration schedules for ALKS 5461. Efficacy endpoints, including the change in Montgomery Asberg Depression Rating Scale (MADRS) total score from baseline and the Clinical Global Impression “Severity Scale (CGI-S) score at Week Eight, were assessed in exploratory analyses. All participants in the double-blind portion of the study were eligible to continue in an open-label phase and receive ALKS 5461 for an additional 12 months. The objective of the extension phase of the study is to assess the safety and long-term durability of effect of ALKS 5461.

Alkermes plc Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 07:30 AM

Alkermes plc Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 07:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Richard F. Pops, Chairman of the Board and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $72.25 USD +0.06

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $97.16 USD -2.49
Impax Laboratories Inc $36.67 USD -1.02
Jazz Pharmaceuticals PLC $169.34 USD -2.73
Lupin Ltd 1,585 INR +30.75
Salix Pharmaceuticals Ltd $134.67 USD -0.47
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.2x
Price/Book 7.9x
Price/Cash Flow 566.3x
TEV/Sales 16.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.